CVS

CVS HEALTH
D

CVS

Arincen56/100B
83.870
USD
2.53
(3.11%)
Post Trading·84.200USD+0.330(+0.39%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q3 FY2026 results
EPS2.09+26.7%Revenue108.40B+3.5%
OverviewFinancialsNewsForecastEarningsDividendsCompany

CVS HEALTH stock forecast 2026–2030

Analysts' average 12-month price target for CVS HEALTH is 109.89, 31.0% above the current price of 83.87. Their targets range from 92.00 to 123.00.

Of the 17 firms that rated CVS HEALTH in the past 12 months, 17 rate it buy or strong buy, 0 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.

12-month price target
109.89 USD
+31.02%

Analysts' 1-year price targets range from 92.00 to 123.00, with an average of 109.89.

Past year
1-year forecast
Strong sellStrong buy
Strong buy
17 ratings
Strong buy
0
Buy
17
Hold
0
Sell
0
Strong sell
0

12-month price target

Highest target123.00
Average target109.89
Lowest target92.00
Current price83.87

CVS HEALTH price target history

Have analysts recently raised or lowered their CVS HEALTH price target and rating?

See how analysts moved their price target

How analysts rate CVS HEALTH, month by month

17 of 17 firms rate it buy now, against 15 of 16 in December 2025.

Buy Hold Sell

Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.

Month endBuyHoldSellFirms
Nov 2026170017
Oct 2026170017
Sept 2026160016
Aug 2026160016
Jul 2026160016
Jun 2026160016
May 2026170017
Apr 2026170017
Mar 2026170017
Feb 2026161017
Jan 2026171018
Dec 2025151016

CVS HEALTH analyst upgrades, downgrades and price targets

The latest rating change came on 12 March 2026, when Bernstein upgraded CVS HEALTH from Market Perform to Outperform. The most recent new target came from Raymond James on 6 November 2026: 103.00.

DateFirmRatingPrice targetChangePrice then
6 Nov 2026
Raymond James
John Ransom
—120.00 → 103.00-14.2%81.33
4 Nov 2026
Jefferies
Brian Tanquilut
—103.00—79.96

CVS HEALTH EPS and revenue estimates

Analysts expect CVS HEALTH's EPS to grow 91.1% a year until 2028. Over the last 5 years it fell 23.9% a year, and over the last 3 years it fell 24.7%.

Analysts expect CVS HEALTH's revenue to grow 3.8% a year until 2028, slower than over the last 5 years (8.4% a year) and the last 3 years (7.6%).

Revenue

ReportedEstimate

EPS

ReportedEstimate
Fiscal yearEPSEPS growthEPS rangeRevenueRevenue growthRevenue rangeAnalysts
FY2028 (est.) 9.70+13.8%8.93 – 10.87 449.26B+4.5%424.68B – 476.95B13
FY2027 (est.) 8.53+5.9%8.46 – 8.94 429.85B+2.9%423.33B – 435.36B18
FY2026 (est.) 8.05+19.2%7.97 – 8.18 417.68B+3.9%414.05B – 422.64B17
FY2025 6.75+24.5%— 402.07B+7.8%——
FY2024 5.42-38.0%— 372.81B+4.2%——
FY2023 8.74+0.5%— 357.78B+10.9%——
FY2022 8.70—— 322.47B———

Does CVS HEALTH beat earnings estimates?

On average, analysts' EPS estimate was 21.2% off the result, either way, and their revenue estimate 3.0%, over the last 12 quarters.

EPS beats
96 / 136
Revenue beats
101 / 120
Average EPS surprise, last 12
+13.4%
Since
February 1993
QuarterReport dateEPS estimateReported EPSSurpriseRevenue estimateReported revenueSurprise
Q3 FY20264 Nov 20261.652.09+26.7%104.72B108.40B+3.5%
Q2 FY20265 Aug 20261.852.58+39.5%100.03B106.10B+6.1%
Q1 FY20266 May 20262.182.57+17.9%94.99B100.43B+5.7%
Q4 FY202510 Feb 20261.001.09+9.0%103.70B105.69B+1.9%
Q3 FY202529 Oct 20251.371.60+16.8%98.81B102.87B+4.1%
Q2 FY202531 Jul 20251.461.81+24.0%94.53B98.92B+4.6%
Q1 FY20251 May 20251.702.25+32.4%93.68B94.59B+1.0%
Q4 FY202412 Feb 20250.911.19+30.2%97.09B97.71B+0.6%
Q3 FY20246 Nov 20241.441.09-24.3%92.75B95.43B+2.9%
Q2 FY20247 Aug 20241.731.83+5.8%91.41B91.23B-0.2%
Q1 FY20241 May 20241.701.31-22.9%89.33B88.44B-1.0%
Q4 FY20237 Feb 20242.012.12+5.5%90.36B93.81B+3.8%

CVS HEALTH stock price 2026–2030: scenarios

If CVS HEALTH's earnings keep growing at the 12.9% a year analysts expect to FY2028, it would earn about 12.36 a share in FY2030. At the P/E it has traded at over the last five years (12.2 to 56.7) that is 150.39 to 700.69 a share, or 313.07 at its average P/E of 25.3. This is arithmetic on the analysts' estimates, not a prediction.

Bull Base Bear
Fiscal yearEPSBearBaseBull
FY2026 8.0597.93203.87456.28
FY2027 8.53103.72215.92483.25
FY2028 9.70118.06245.78550.08
FY2029 (extrapolated)10.95133.25277.39620.84
FY2030 (extrapolated)12.36150.39313.07700.69

Each year's EPS is the analysts' consensus to FY2028; the years after continue its 12.9% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (12.2, 25.3, 56.7).

Is CVS HEALTH stock undervalued or overvalued?

CVS HEALTH's P/E of 9.7 is near the bottom of its 5-year range (9.4 to 202.1, median 16.5). It is within 5% of its 5-year low. Analysts do not expect slower growth than in recent years, so it is cheaper than its usual level. Fair value is not a reliable guide for CVS HEALTH: its earnings swing (EPS fell ⁦62.0%⁩ in FY2025), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 10.4.

Price to earnings ratio (TTM)
9.68
Five-year median P/E
16.49
Five-year P/E range
9.4 – 202.1
Forward P/E (FY2026)
10.42
PEG ratio
0.75
To the average target
+31.0%
See the full P/E history check Plus

Most undervalued US stocks

StockPriceFair valueUpside
99.090
195.10146Price 99.09244
+96.9%
186.680
359.93270Price 186.68450
+92.8%
213.670
405.66304Price 213.67507
+89.9%
161.160
305.51157Price 161.16396
+89.6%
42.225
79.0244Price 42.23157
+87.1%
160.650
299.85225Price 160.65375
+86.6%
108.445
201.41108Price 108.45248
+85.7%

Furthest below the fair value on each stock's page, updated every day.

Common questions about the CVS HEALTH stock forecast

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.